Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.

about

Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.

Item

http://www.wikidata.org/entity/Q40043990

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Referral population studies un ...... in primary cervical screening.

@en

type

Item

label

Referral population studies un ...... in primary cervical screening.

@en

prefLabel

Referral population studies un ...... in primary cervical screening.

@en

P1476

Referral population studies un ...... in primary cervical screening

@en

P2093

C Rygaard

http://www.w3.org/2001/XMLSchema#string

D Ejegod

http://www.w3.org/2001/XMLSchema#string

S Njor

http://www.w3.org/2001/XMLSchema#string

S Preisler

http://www.w3.org/2001/XMLSchema#string

P2860

High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.

APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results.

Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities.

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system.

Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening.

Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer

HPV testing by cobas HPV test in a population from Catalonia.

Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.

Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.

Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.

P304

419-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CYT.12451

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elsebeth Lynge

Jesper Bonde

Matejka Rebolj

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28901682

http://www.w3.org/2001/XMLSchema#string

Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.

about

Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698